81/100B547.03
USD
4.03
(0.74%)
Pre Open·549.72USD+2.69(+0.49%)
Last updated: · Delayed 15 min
Vertex Pharmaceuticals financials
Yes. Vertex Pharmaceuticals earned 3.98B USD of net income over the last twelve months, 30.6% of its revenue. It made a profit in 10 of its 36 fiscal years since 1990. Its last loss was in fiscal year 2024.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 12.99B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 3.98B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 3.20B USD
- Cash and short-term investments
- 6.30B USD
- Total debt
- 6.48B USD
- Shareholders' equityWhat is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
- 20.91B USD
Cash, debt and equity as of 30 Sept 2026.
Vertex Pharmaceuticals earnings
Next earnings · Q4 FY2026
EPS estimate
4.23 USD
Revenue estimate
3.50B USD
Last quarter · Q3 FY2026
EPS4.76Missed -1.2%Revenue3.44BBeat +0.6%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 4.64 | — | — | +3.83% | 3.47B | — | — | +16.17% | |
| Q4 FY2026 | 4.23 | — | — | -15.90% | 3.50B | — | — | +9.76% | |
| Q3 FY2026 | 4.82 | 4.76 | -1.24% | -0.83% | 3.42B | 3.44B | +0.62% | +11.85% | |
| Q2 FY2026 | 4.74 | 4.73 | -0.21% | +4.65% | 3.23B | 3.33B | +3.20% | +12.45% | |
| Q1 FY2026 | 4.24 | 4.47 | +5.42% | +10.10% | 2.99B | 2.99B | -0.24% | +7.82% | |
| Q4 FY2025 | 5.11 | 5.03 | -1.57% | +26.38% | 3.18B | 3.19B | +0.18% | +9.55% | |
| Q3 FY2025 | 4.57 | 4.80 | +5.03% | +9.59% | 3.06B | 3.08B | +0.55% | +10.99% | |
| Q2 FY2025 | 4.29 | 4.52 | +5.36% | — | 2.91B | 2.96B | +2.01% | +12.53% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 24.09 | — | — | +19.49% | 16.52B | — | — | +12.51% |
| FY2027 | 20.16 | — | — | +10.59% | 14.68B | — | — | +10.79% |
| FY2026 | 18.23 | — | — | -0.96% | 13.25B | — | — | +10.44% |
| FY2025 | 18.48 | 18.41 | -0.37% | +6,248.28% | 11.98B | 12.00B | +0.14% | +9.05% |
| FY2024 | 0.46 | 0.29 | -36.45% | -98.09% | 10.89B | 11.01B | +1.06% | +11.52% |
| FY2023 | 15.03 | 15.22 | +1.24% | +2.22% | 9.86B | 9.87B | +0.06% | +10.51% |
| FY2022 | 14.60 | 14.89 | +1.98% | +14.36% | 8.93B | 8.93B | -0.03% | +17.91% |
Vertex Pharmaceuticals growth and profitability
Full income statement- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 12.99B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 3.98B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 85.57%
- Operating margin
- 33.87%
- Net margin
- 30.61%
Revenue / Net income
Revenue Net income Net margin
How Vertex Pharmaceuticals makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
TRIKAFTA/KAFTRIO10.31B 85.4%
ALYFTREK837.80M 6.9%
Manufactured Product, Other820.10M 6.8%
Revenue12.07B 100.0%
Cost of revenue1.81B 15.0%
Gross profit10.27B 85.0%
Research and development3.75B 31.1%
Selling and administration1.75B 14.5%
Operating income4.76B 39.4%
Tax690.00M 5.7%
Other expense117.50M 1.0%
Net income3.95B 32.7%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Vertex Pharmaceuticals revenue breakdown
By product
FY2025
86.2%TRIKAFTA/KAFTRIO7.0%ALYFTREK6.9%Manufactured Product, Other
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| TRIKAFTA/KAFTRIO | 10.31B | 86.2% | +0.7% |
| ALYFTREK | 837.80M | 7.0% | — |
| Manufactured Product, Other | 820.10M | 6.9% | +4.9% |
By region
FY2025
45.9%United States33.1%Non-US21.0%Europe
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 7.55B | 45.9% | +12.9% |
| Non-US | 5.45B | 33.1% | — |
| Europe | 3.46B | 21.0% | +0.2% |
Operating and free cash flow
Full cash flow statementOperating cash flow Free cash flow
Vertex Pharmaceuticals financial health
Full balance sheet- Cash and short-term investments
- 6.30B USD
- Total debt
- 6.48B USD
- Net cash
- -175.10M USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 3.20B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 2.34
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.31
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 4 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 8.86
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Assets, liabilities and equity
Total assets Total liabilities Shareholders' equity
Vertex Pharmaceuticals valuation
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 34.93
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 30.00
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 10.67
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 6.63
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 27.95
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
138.65B USD
+
Total debt
6.48B USD
−
Cash and short-term investments
6.30B USD
=
Enterprise value
138.83B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Vertex Pharmaceuticals against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Moderna, Regeneron Pharmaceuticals, Revolution Medicines, United Therapeutics, Incyte, and Insmed, the US Biotechnology companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginLowest in 5 years85.0%85.0%88.1%Against its peers: 5 of 7Peers' median 86.6%
- Operating marginAbove its median39.4%-2.1%48.2%Against its peers: 2 of 7Peers' median -66.6%
- Net marginAt its median32.7%-4.9%37.2%Against its peers: 2 of 7Peers' median -60.1%
- Return on equityAt its median21.2%-3.3%23.9%Against its peers: 2 of 7Peers' median -4.7%
- Free cash flow marginBelow its median26.5%-7.2%44.0%Against its peers: 3 of 7Peers' median -39.9%
- Revenue growthLowest in 5 years9.6%9.6%22.1%Against its peers: 4 of 7Peers' median 5.8%
- Debt to EBITDAAbove its median0.80×0.18×3.60×Against its peers: 4 of 4Peers' median 0.04×
- Current ratioBelow its median2.902.694.83Against its peers: 7 of 7Peers' median 3.98
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Vertex Pharmaceuticals ownership
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 95.84%
- Institutional holders
- 1,831 (+62)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.77%
Who owns the shares
Institutions 95.8% Others 4.2%
As of 30 Jun 2026
Shares free to trade
Free float 252.88M shares ·99.8% Closely held 579.41K shares ·0.2%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 0 | 916.97 | 0.00 |
| Q3 2026 | 0 | 3 | 30.32K | 9.87K |
| Q2 2026 | 0 | 11 | 22.07K | 22.96K |
| Q1 2026 | 0 | 56 | 261.02K | 323.45K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Common questions about Vertex Pharmaceuticals's financials
Source: Financial Modeling Prep